Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company shows strong growth across product lines, increased revenue guidance, and improved EBITDA margins. The Q&A reveals excitement around On-X's unique clinical data and AMDS's strong demand. Although management avoided specific 2026 guidance, the positive outlook for product launches and market expansions supports a positive sentiment. With a market cap of approximately $1 billion, the stock is likely to react positively, with a predicted movement of 2% to 8%.
Key Financial Performance
Total revenues $113.4 million for Q3 2025, up approximately 16% compared to Q3 2024. Growth driven by strong performance across product lines.
Adjusted EBITDA Increased approximately 39% from $17.7 million to $24.6 million in Q3 2025. Adjusted EBITDA margin improved by approximately 320 basis points to 21.7%, driven by gross margin improvements and SG&A leverage.
Stent graft revenues Increased 31% year-over-year in Q3 2025. Growth driven by AMDS adoption and initial stocking orders.
On-X revenues Grew 23% year-over-year in Q3 2025. Growth attributed to global market share gains and unique clinical profile of the On-X valve.
Tissue processing revenues Increased 5% year-over-year in Q3 2025. Growth attributed to SynerGraft pulmonary valves, with demand outstripping supply.
BioGlue revenues Grew 1% year-over-year in Q3 2025. Growth variability due to stock and distributor business.
Gross margins 65.6% in Q3 2025, up from 63.7% in Q3 2024. Improvement driven by favorable mix from AMDS HDE revenues and On-X growth.
Free cash flow $17.7 million in Q3 2025. Full-year 2025 expected to be slightly cash flow negative due to a $12 million facility purchase, but free cash flow positive in 2026.
Net leverage ratio 1.8 at the end of Q3 2025, down from 3.9 in the prior year. Improvement due to refinancing and operational performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Stent graft revenues: Grew 31% on a constant currency basis in Q3 2025, driven by AMDS adoption and initial stocking orders. AMDS is seen as a foundational growth component.
AMDS U.S. launch: Received HDE in late 2024, with strong market enthusiasm and positive clinical data. Estimated $150 million annual U.S. market opportunity.
On-X valves: Revenue grew 23% year-over-year in Q3 2025, driven by global market share gains and unique clinical profile. Positioned as the best aortic valve for patients under 65.
Geographic revenue growth: North America grew 19%, Asia Pacific 18%, EMEA 12%, and Latin America 10% in Q3 2025.
Expansion in Austin, Texas: Purchased two facilities to expand On-X manufacturing operations, ensuring long-term capacity and stability.
Adjusted EBITDA: Increased 39% year-over-year in Q3 2025, reaching $24.6 million. Margin improved to 21.7%.
Gross margins: Improved to 65.6% in Q3 2025, driven by favorable mix from AMDS and On-X growth.
Free cash flow: $17.7 million in Q3 2025, with expected cash flow positivity in 2026 despite facility purchases.
Pipeline advancements: Filed 3 of 4 modules for AMDS PMA, with FDA approval expected in mid-2026. NEXUS device on track for approval in H2 2026.
Clinical trials: Launched ARTIZEN pivotal trial for Arcevo LSA, targeting acute and chronic arch pathologies.
Credit facility amendment: Extended maturity to 2031, secured favorable interest rates, and gained access to a $150 million term loan for potential Endospan acquisition.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cybersecurity Incident: The 2024 cybersecurity event caused disruptions in tissue processing volumes earlier in the year. Although volumes have normalized, the incident highlights vulnerabilities in operational continuity and potential risks to supply chain and data security.
Regulatory and Approval Risks: The company is awaiting FDA approval for key products like AMDS and NEXUS, with timelines extending to mid-2026 and late 2026, respectively. Delays or failure to secure these approvals could impact market expansion and revenue growth.
Supply Constraints: Demand for SynerGraft pulmonary valves outstrips supply every quarter, leading to no inventory availability. This supply constraint could limit revenue growth and customer satisfaction.
Economic and Financial Risks: The company has taken on significant debt, with $214.9 million in net debt and a net leverage ratio of 1.8. While refinancing has improved terms, the financial burden and reliance on future cash flows to service debt remain risks.
Market Competition: The company faces limited competitive alternatives in some markets, but any new entrants or advancements by competitors could erode market share, particularly in the AMDS and On-X product lines.
Operational Expansion Risks: The company is expanding its operational footprint in Austin, Texas, to meet rising capacity needs. However, this expansion involves significant upfront costs and could face delays or cost overruns.
Reimbursement and Pricing Risks: While CMS has established a new reimbursement code for AMDS, any changes in reimbursement policies or rates could impact the economic value proposition and patient access.
Clinical Trial Dependencies: The success of ongoing clinical trials like ARTIZEN and NEXUS is critical for future product launches. Any unfavorable trial outcomes could delay or derail product commercialization plans.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects constant currency revenue growth between 13% and 14% for the full year 2025, with reported revenues projected to be in the range of $439 million to $445 million. Double-digit revenue growth is also anticipated for 2026.
Adjusted EBITDA: Full year 2025 adjusted EBITDA is expected to be in the range of $88 million to $91 million, representing 24% to 28% growth over 2024. Adjusted EBITDA is expected to grow at twice the rate of constant currency revenue growth in 2026.
AMDS U.S. Market Opportunity: The company is targeting a $150 million annual U.S. market opportunity for AMDS, supported by new clinical data, reimbursement updates, and limited competitive alternatives. FDA approval for AMDS PMA is expected by mid-2026.
On-X Heart Valve Growth: On-X heart valve revenue is expected to continue growing, driven by global market share gains and new clinical data supporting its use in younger patients. The company is pursuing a $100 million annual market opportunity for On-X valves in patients under 60.
NEXUS PMA and Market Opportunity: Endospan is expected to present 1-year clinical data for the NEXUS device in January 2026, with FDA approval anticipated in the second half of 2026. This represents a $150 million annual U.S. market opportunity.
Arcevo LSA IDE Trial: The company has initiated the pivotal trial for its third-generation frozen elephant trunk device, Arcevo, which will evaluate its safety and effectiveness. This trial is expected to support future growth.
Operational Expansion: The company has purchased two facilities in Austin, Texas, to expand its On-X manufacturing operations, ensuring long-term capacity and stability.
2026 Expense Dynamics: The company anticipates higher expenses in 2026 due to the full-year costs of the CVO trial and year 2 of the AMDS launch, which will result in more difficult year-over-year comparisons.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the annualized cost of the Arcevo trial and the growth implications for AMDS?
A:The Arcevo trial is funded through R&D investments at a rate of 7%-8% of sales annually. This year, the spending is at the low end of the range due to a few months of clinical trials, but next year it may push to the higher end. For AMDS, growth is strong due to smaller numbers this year compared to zero in the prior year, but growth rates will normalize as prior year numbers are factored in.
Q:What is driving the 20%+ growth rate for On-X?
A:The growth is driven by market share gains due to On-X being the only aortic valve with a low INR indication from the FDA, new clinical data showing mortality benefits for mechanical valves over bioprosthetic valves in younger patients, and excitement among cardiologists and surgeons about the clinical data.
Q:What are the implications of the new DRG-209 for advanced aortic arch procedures?
A:The new DRG-209 reflects the high cost and complexity of advanced aortic arch procedures, providing a tailwind for the company by reducing cost constraints and validating the value of their product portfolio in this segment.
Q:What is the status of the NEXUS technology and its potential acquisition?
A:The NEXUS technology is under FDA review with a PMA expected in the second half of 2026. The company has set up financial arrangements for a potential acquisition but will decide based on approval and label outcomes. Clinical feedback has been positive, and the technology is seen as a platform with multiple products.
Q:What is the current status of AMDS adoption and its impact on revenue?
A:AMDS revenue is currently heavily weighted towards initial stocking, with increasing implantation rates. Feedback from early adopters has been excellent, and the product is trending towards the high end of initial expectations.
Q:What is the timeline for AMDS expansion into international markets like Japan and China?
A:The company is focusing on obtaining U.S. PMA approval first, with plans to pursue Japan PMA and reimbursement subsequently. No specific timeline for China has been provided.
Q:What are the growth expectations for 2026 and the factors influencing gross margin improvements?
A:Growth in 2026 is expected to align with the annual growth rate for 2023, without an accelerating trend. Gross margin improvements are driven by product mix, particularly the growth of high-margin products like AMDS and On-X in the U.S.
Q:What are the cross-selling benefits and marketing plans for On-X?
A:On-X has seen consistent growth, with new accounts showing positive utilization trends. Marketing efforts are currently focused on surgeons, with plans to target cardiologists in 2026 to further leverage the new clinical data.
Q:What is the recruitment pace and market size for the Arcevo trial?
A:The Arcevo trial involves 130 patients across 30 centers, with enrollment expected over 12-18 months. The U.S. frozen elephant trunk market, which Arcevo targets, is estimated at $80 million.
Q:What is the outlook for the tissue business?
A:The tissue business has normalized to 5% growth but is expected to be flat for the full year due to backlog recovery from a prior cyber event. Mid-single-digit growth is anticipated next year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific growth guidance for 2026, stating only that growth dynamics would be similar to 2023. They also did not disclose specific numbers for AMDS adoption or On-X marketing plans targeting cardiologists, citing early stages or appropriateness of disclosure.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMDS PERSEVERE
Annual Meeting
Artivion
COO CFO
DRG
EX AMDS
access draw
acquisition
adoption
anticipation
business
credit
draw term
elephant trunk
engine
facility Austin
flow cash
generation elephant
interest rate
life
loan facility
maturity
opportunity AMDS
patient malperfusion
payment
point improvement
procedure
purchase
result AMDS
result currency
subset
term capacity
term loan
value proposition
AORT Transcript
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Unknown5-10
The earnings call summary presents a mixed picture: positive trends in gross margins, reduced interest expenses, and improved cash flow are offset by challenges such as international stent graft sales and AMDS starter set barriers. The Q&A highlights cautious guidance due to geopolitical and supply chain issues. While the company is optimistic about future product launches, current uncertainties and management's reluctance to provide detailed guidance suggest a neutral market reaction. Given the small market cap, any positive or negative developments could lead to more pronounced stock movements.
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call reveals strong financial performance, optimistic guidance, and strategic product development, especially with AMDS and NEXUS. The Q&A section highlights management's confidence in market opportunities and competitive positioning. Despite some unclear responses, the overall tone is positive. With a market cap of ~$1 billion, the stock is likely to see a positive reaction, in the 2% to 8% range, over the next two weeks.
Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript
Positive11-6
The company shows strong growth across product lines, increased revenue guidance, and improved EBITDA margins. The Q&A reveals excitement around On-X's unique clinical data and AMDS's strong demand. Although management avoided specific 2026 guidance, the positive outlook for product launches and market expansions supports a positive sentiment. With a market cap of approximately $1 billion, the stock is likely to react positively, with a predicted movement of 2% to 8%.
Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-10
AORT Slides
AORT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
